title: Laparoscopic ileocolic resection versus infliximab treatment of distal ileitis in Crohn's disease: a randomized multicenter trial (LIR!C-trial).
abstract: BACKGROUND
  With the availability of infliximab, nowadays recurrent Crohn's disease, defined as disease refractory to immunomodulatory agents that has been treated with steroids, is generally treated with infliximab. Infliximab is an effective but expensive treatment and once started it is unclear when therapy can be discontinued. Surgical resection has been the golden standard in recurrent Crohn's disease. Laparoscopic ileocolic resection proved to be safe and is characterized by a quick symptom reduction. The objective of this study is to compare infliximab treatment with laparoscopic ileocolic resection in patients with recurrent Crohn's disease of the distal ileum with respect to quality of life and costs.
  
  
  METHODS
  The study is designed as a multicenter randomized clinical trial including patients with Crohn's disease located in the terminal ileum that require infliximab treatment following recent consensus statements on inflammatory bowel disease treatment: moderate to severe disease activity in patients that fail to respond to steroid therapy or immunomodulatory therapy. Patients will be randomized to receive either infliximab or undergo a laparoscopic ileocolic resection. Primary outcomes are quality of life and costs. Secondary outcomes are hospital stay, early and late morbidity, sick leave and surgical recurrence. In order to detect an effect size of 0.5 on the Inflammatory Bowel Disease Questionnaire at a 5% two sided significance level with a power of 80%, a sample size of 65 patients per treatment group can be calculated. An economic evaluation will be performed by assessing the marginal direct medical, non-medical and time costs and the costs per Quality Adjusted Life Year (QALY) will be calculated. For both treatment strategies a cost-utility ratio will be calculated. Patients will be included from December 2007.
  
  
  CONCLUSIONS
  The LIR!C-trial is a randomized multicenter trial that will provide evidence whether infliximab treatment or surgery is the best treatment for recurrent distal ileitis in Crohn's disease.
  
  
  BACKGROUND
  Nederlands Trial Register NTR1150.
authors: Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, The Netherlands. e.j.eshuis@amc.uva.nl
authors: Emma J
authors: EJ
authors: Eshuis
authors: Willem A
authors: WA
authors: Bemelman
authors: Ad A
authors: AA
authors: van Bodegraven
authors: Mirjam A G
authors: MA
authors: Sprangers
authors: Patrick M M
authors: PM
authors: Bossuyt
authors: A W Marc
authors: AW
authors: van Milligen de Wit
authors: Rogier M P H
authors: RM
authors: Crolla
authors: Djuna L
authors: DL
authors: Cahen
authors: Liekele E
authors: LE
authors: Oostenbrug
authors: Meindert N
authors: MN
authors: Sosef
authors: Annet M C J
authors: AM
authors: Voorburg
authors: Paul H P
authors: PH
authors: Davids
authors: C Janneke
authors: CJ
authors: van der Woude
authors: Johan
authors: J
authors: Lange
authors: Rosalie C
authors: RC
authors: Mallant
authors: Maarten J
authors: MJ
authors: Boom
authors: Rob J
authors: RJ
authors: Lieverse
authors: Edwin S
authors: ES
authors: van der Zaag
authors: Martin H M G
authors: MH
authors: Houben
authors: Juda
authors: J
authors: Vecht
authors: Robert E G J M
authors: RE
authors: Pierik
authors: Theo J M
authors: TJ
authors: van Ditzhuijsen
authors: Hubert A
authors: HA
authors: Prins
authors: Willem A
authors: WA
authors: Marsman
authors: Henricus B
authors: HB
authors: Stockmann
authors: Menno A
authors: MA
authors: Brink
authors: Esther C J
authors: EC
authors: Consten
authors: Sjoerd D J
authors: SD
authors: van der Werf
authors: Andreas W K S
authors: AW
authors: Marinelli
authors: Jeroen M
authors: JM
authors: Jansen
authors: Michael F
authors: MF
authors: Gerhards
authors: Clemens J M
authors: CJ
authors: Bolwerk
authors: Laurents P S
authors: LP
authors: Stassen
authors: B W Marcel
authors: BW
authors: Spanier
authors: Ernst Jan Spillenaar
authors: EJ
authors: Bilgen
authors: Anne-Marie
authors: AM
authors: van Berkel
authors: Huib A
authors: HA
authors: Cense
authors: Henk A
authors: HA
authors: van Heukelem
authors: Arnold
authors: A
authors: van de Laar
authors: Warner Bruins
authors: WB
authors: Slot
authors: Quirijn A
authors: QA
authors: Eijsbouts
authors: Nancy A M
authors: NA
authors: van Ooteghem
authors: Bart
authors: B
authors: van Wagensveld
authors: Jan M H
authors: JM
authors: van den Brande
authors: Anna A W
authors: AA
authors: van Geloven
authors: Karien F
authors: KF
authors: Bruin
authors: John K
authors: JK
authors: Maring
authors: Bas
authors: B
authors: Oldenburg
authors: Richard
authors: R
authors: van Hillegersberg
authors: Dirk J
authors: DJ
authors: de Jong
authors: Robert
authors: R
authors: Bleichrodt
authors: Donald L
authors: DL
authors: van der Peet
authors: Pascal E P
authors: PE
authors: Dekkers
authors: T Hauwy
authors: TH
authors: Goei
authors: Pieter C F
authors: PC
authors: Stokkers
mesh_terms: D000893:Anti-Inflammatory Agents / Q000191:economics / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000191:economics / Q000627:therapeutic use*; D003106:Colon / Q000601:surgery*; D003424:Crohn Disease / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D006801:Humans; D007082:Ileum / Q000601:surgery*; D000069285:Infliximab; D010535:Laparoscopy / Q000191:economics*; D011788:Quality of Life; D012008:Recurrence
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D000069285:Infliximab